Five CRISPR-edited PRV mutants clarify gene-by-gene effects

Version 2

A new Veterinary Sciences paper takes a comparative approach to pseudorabies virus genetics, examining five CRISPR/Cas9-generated PRV mutants derived from the same JM strain and individually disrupting UL21, UL24, UL50, UL56, or gG/US4. By holding the viral backbone constant, the authors aimed to isolate how each gene affects growth and virulence-linked phenotypes, an important step in sorting out which deletions are most useful for attenuation studies and future vaccine engineering. (pmc.ncbi.nlm.nih.gov)

That question has practical relevance because PRV gene editing is no longer a niche laboratory exercise. CRISPR/Cas9 has become a standard tool for manipulating the large PRV genome, supporting everything from mechanistic studies to construction of live-attenuated and vectored vaccine candidates. Prior PRV work has used CRISPR to generate mutants affecting UL13, UL41, gE, gI, TK, and other loci, while a recent JM-strain study described recombinant JM viruses with multiple virulence-gene deletions for evaluation in mice and piglets. (pubmed.ncbi.nlm.nih.gov)

The broader biology also helps explain why these five targets are worth comparing. PRV is a neurotropic alphaherpesvirus of swine that can also infect a wide range of non-porcine mammals. Reviews of PRV pathogenesis and immunity describe roles for tegument and envelope proteins in replication, neuroinvasion, cell-to-cell spread, and immune evasion. Published background specifically links UL24 to suppression of innate immune signaling, UL50 to antagonism of type I interferon responses, and gG to virulence- and immunobiology-related functions that have made it a recurring deletion target in recombinant PRV design. (pmc.ncbi.nlm.nih.gov)

Even without a major press release or outside quote tied directly to this paper, the study fits a clear industry and research trend: moving from broad “gene-deleted PRV” concepts toward more precise, gene-by-gene phenotypic maps. That trend is visible in recent commentary and reviews arguing that additional deletions beyond the classic gE/gI/TK set, including genes such as UL24, US2, US9, and gG, may improve attenuation or immunogenicity profiles in next-generation constructs. (frontiersin.org)

Why it matters: For veterinarians and animal health professionals, this paper is most relevant as enabling science. It doesn’t change current herd-level pseudorabies control protocols, but it does strengthen the evidence base behind which viral genes are worth targeting in future vaccines, challenge models, and possibly differentiated diagnostic strategies. That matters most in countries still managing variant PRV circulation, but it also has surveillance relevance elsewhere because PRV remains entrenched in feral swine reservoirs and can spill into domestic pigs and other mammals. USDA APHIS continues to describe pseudorabies as a reportable swine disease concern, and recent U.S. updates tied to detections in small herds underscore that eradication from commercial herds did not eliminate exposure risk. (aphis.usda.gov)

For swine veterinarians, the practical takeaway is that attenuation is not one-size-fits-all. Different gene disruptions can affect replication kinetics, plaque morphology, syncytium formation, neurovirulence, or innate immune antagonism in different ways, which means the choice of deletion matters when interpreting experimental challenge data or evaluating future vaccine claims. Earlier JM-strain and other PRV mutant studies have already shown that some deletions preserve growth while reducing spread or virulence, while others more sharply depress replication, reinforcing the need for side-by-side characterization like the new paper provides. (pmc.ncbi.nlm.nih.gov)

What to watch: The next step is whether these single-gene JM mutants move into in vivo validation and whether any of the disrupted loci are folded into multi-gene recombinant candidates for pigs, not just cell culture or mouse models. If that happens, the field will be closer to identifying which combinations best balance safety, manufacturability, immunogenicity, and DIVA-style utility for modern PRV control programs. (mdpi.com)